| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Cheif Financial Officer | Common Stock | 48.1K | $38.5K | $0.80 | Mar 1, 2023 | Direct |
| Inhibikase Therapeutics, Inc. | Cheif Financial Officer | Stock Option (right to buy) | 90K | Mar 1, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | Mar 1, 2023 | 1 | $0 | 4 | Mar 3, 2023 | Cheif Financial Officer |
| IKT | Inhibikase Therapeutics, Inc. | May 19, 2022 | 1 | $2.54K | 4 | May 23, 2022 | Chief Financial Officer |
| IKT | Inhibikase Therapeutics, Inc. | Mar 7, 2022 | 1 | $0 | 4 | Mar 21, 2022 | Chief Financial Officer |
| IKT | Inhibikase Therapeutics, Inc. | Mar 7, 2022 | 1 | $0 | 4 | Mar 9, 2022 | Cheif Financial Officer |